论文部分内容阅读
支气管哮喘是常见的慢性呼吸道疾病,与气道高反应性的发生和发展有关。全身应用糖皮质激素对缓解支气管哮喘发作已被作为首选[1],而其抗炎作用存在不足,且可促进胃酸,减少胃黏液分泌,诱发或加剧食道反流。此机制被证实与支气管哮喘相关[2]。孟鲁斯特可针对糖质皮激素的抗炎作弥补。奥美拉唑能有效抑制胃酸分泌、缓解食道反流引发的过敏性哮喘[3]。本研究对2013年6月至2015年3月收治的68例哮喘患者,常规平喘、抗炎治疗基础上,通过对比常规治疗与加用奥美拉唑和孟鲁斯特的临床疗效观察,进行评价。
Bronchial asthma is a common chronic respiratory disease, and the occurrence and development of airway hyperresponsiveness. Systemic use of glucocorticoids to alleviate bronchial asthma attacks has been as the first choice [1], and its anti-inflammatory effects of inadequate, and can promote gastric acid, reduce gastric mucus secretion, induce or aggravate esophageal reflux. This mechanism has been shown to be associated with bronchial asthma [2]. MONTERSTAR can make up for the anti-inflammatory glucocorticoid. Omeprazole can effectively inhibit gastric acid secretion, relieve allergic asthma caused by esophageal reflux [3]. The study of 68 patients with asthma admitted from June 2013 to March 2015, based on conventional antiasthmatic and anti-inflammatory treatment, compared with the conventional treatment and the application of omeprazole and Montelukast clinical curative effect, Evaluation.